home / stock / xbio / xbio quote
Last: | $4.15 |
---|---|
Change Percent: | 7.51% |
Open: | $3.92 |
Close: | $3.86 |
High: | $4.15 |
Low: | $3.92 |
Volume: | 1,350 |
Last Trade Date Time: | 04/18/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$4.15 | $3.92 | $3.86 | $4.15 | $3.92 | 1,350 | 04-18-2024 |
$3.86 | $4.2999 | $3.86 | $4.2999 | $3.8125 | 2,773 | 04-17-2024 |
$4.015 | $3.91 | $4.015 | $4.015 | $3.82 | 2,611 | 04-16-2024 |
$4.14 | $4.11 | $4.14 | $4.315 | $4.11 | 9,138 | 04-15-2024 |
$4.33 | $4.46 | $4.33 | $4.46 | $4.33 | 1,419 | 04-12-2024 |
$4.4292 | $4.56 | $4.4292 | $4.56 | $4.3401 | 7,140 | 04-11-2024 |
$4.6859 | $4.64 | $4.6859 | $4.6859 | $4.64 | 5,272 | 04-10-2024 |
$4.72 | $4.66 | $4.72 | $4.73 | $4.65 | 1,528 | 04-09-2024 |
$4.65 | $4.62 | $4.65 | $4.74 | $4.62 | 3,917 | 04-08-2024 |
$4.63 | $4.48 | $4.63 | $4.6399 | $4.4105 | 2,487 | 04-05-2024 |
$4.4001 | $4.71 | $4.4001 | $4.71 | $4.4001 | 3,481 | 04-04-2024 |
$4.62 | $4.39 | $4.62 | $4.64 | $4.31 | 31,818 | 04-03-2024 |
$4.39 | $4.15 | $4.39 | $4.467 | $4.15 | 20,170 | 04-02-2024 |
$4.2 | $3.8059 | $4.2 | $4.2 | $3.8059 | 18,346 | 04-01-2024 |
$3.77 | $3.8965 | $3.77 | $3.8999 | $3.77 | 3,948 | 03-29-2024 |
$3.77 | $3.8965 | $3.77 | $3.8999 | $3.77 | 3,948 | 03-28-2024 |
$3.98 | $3.96 | $3.98 | $4.17 | $3.96 | 9,311 | 03-27-2024 |
$3.82 | $3.99 | $3.82 | $4 | $3.77 | 4,818 | 03-26-2024 |
$3.95 | $3.76 | $3.95 | $4 | $3.75 | 8,852 | 03-25-2024 |
$3.86 | $3.65 | $3.86 | $3.9638 | $3.65 | 2,900 | 03-22-2024 |
News, Short Squeeze, Breakout and More Instantly...
Xenetic Biosciences Inc. Company Name:
XBIO Stock Symbol:
NASDAQ Market:
Xenetic Biosciences Inc. Website:
Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the year with $9.0 million of cash to fund operations FRAMINGHAM, MA / ACCESSWIRE / March 22, 2024 /...
- Company building growing body of preclinical data to guide pathway to first in human trial for DNase-based oncology platform FRAMINGHAM, MA / ACCESSWIRE / January 17, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advan...
Encouraging growing body of preclinical data guiding pathway to first in human trial for DNase-based oncology platform Driving development towards Phase 1 program for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Continuing partnering discus...